Immunocore Holdings PLC Form 4 insider transactions

Travis Alan Coy, Chief Financial Officer of Immunocore Holdings plc, reports the acquisition of employee share options.

Baker Bros. Advisors and related entities report the acquisition of non-qualified share options for Immunocore Holdings, granted to Ranjeev Krishana, an employee of Baker Bros. Advisors LP and a director of Immunocore.

Director Siddharth Kaul acquired 14,534 share options in Immunocore Holdings plc on May 23, 2024, at an exercise price of $50.47.

Director Peter John Ratcliffe acquired 14,534 share options in Immunocore Holdings plc on May 23, 2024.

Kristine Peterson, a director at Immunocore Holdings plc, acquired 14,534 shares through a share option award on May 23, 2024.

Director Roy Steven Herbst acquired share options in Immunocore Holdings plc on May 23, 2024.

Director John Irving Bell acquired share options in Immunocore Holdings plc on May 23, 2024.

Tina St Leger, Chief HR Officer of Immunocore Holdings plc, exercised stock options and sold shares on April 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

David M. Berman, Head of R&D at Immunocore Holdings plc, executed transactions involving ordinary shares, including exercising options and selling shares, under a pre-arranged 10b5-1 trading plan.

David M. Berman, Head of R&D at Immunocore Holdings plc, executed sales of ordinary shares on February 26 and 27, 2024, under a pre-arranged Rule 10b5-1 trading plan.